Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A.
Haupenthal J, et al. Among authors: vogl tj.
Neoplasia. 2012 May;14(5):410-9. doi: 10.1596/neo.111366.
Neoplasia. 2012.
PMID: 22745587
Free PMC article.